AN2 Therapeutics, Inc. Common Stock (ANTX) Stock Price

ANTXStock
$3.38+186.44%52W
Market Cap$127.55M
P/E—
PEG Ratio—
Div yield—
Beta-0.95

ANTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.52%
Price vs S&P 500 (4W)-30.53%
VGM Score59.51

ANTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.24-$0.18+25.00%(+$0.06)
Q1 2026-$0.23-$0.29-26.09%(-$0.06)
Q4 2025-$0.24-$0.29-20.83%(-$0.05)
Q3 2025-$0.22-$0.31-40.91%(-$0.09)
Q2 2025-$0.31-$0.21+32.26%(+$0.10)

ANTX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.29
4.29
4.38
4.38

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ANTXAN2 Therapeutics, Inc. Common Stock
——C————$3.38
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About AN2 Therapeutics, Inc. Common Stock

AN2 Therapeutics develops small molecule therapeutics using proprietary boron chemistry, targeting infectious diseases and oncology with significant unmet medical needs. Its pipeline includes programs for Chagas disease, non-tuberculous mycobacterial infections, and melioidosis, with additional early-stage oncology initiatives.